In both cases, daily treatment with XMU-MP-1 for up to a month significantly impaired tumor growth (Fig. 7g–l), suggesting that targeting the Hippo pathway could overcome therapy resistance conferred by the mutant ERα. Here, ESR1 is linked to neoplasm.